Is Teva Pharmaceutical Industries Ltd (TEVA) a Stock to Watch After Losing -1.13% This Week?

Overall market sentiment has been down on Teva Pharmaceutical Industries Ltd (TEVA) stock lately. TEVA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Teva Pharmaceutical Industries Ltd has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TEVA!

See Full TEVA Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With TEVA Stock Today?

Teva Pharmaceutical Industries Ltd (TEVA) stock is down -3% while the S&P 500 is up 0.01% as of 10:26 AM on Wednesday, Sep 14. TEVA is down -$0.27 from the previous closing price of $9.01 on volume of 1,414,690 shares. Over the past year the S&P 500 has fallen -11.99% while TEVA is down -5.92%. TEVA lost -$0.95 per share in the over the last 12 months. To screen for more stocks like Teva Pharmaceutical Industries Ltd click here.

More About Teva Pharmaceutical Industries Ltd

Based in Israel, Teva is one of the world's largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company's branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva's portfolio rationalization has resulted in less overall price erosion versus peers. Click Here to get the full Stock Report for Teva Pharmaceutical Industries Ltd stock.